PK, immunogenicity, and antitumor activity will also be evaluated. The study is currently enrolling at sites in the US, with future enrollment in China planned (NCT05579366).
In summary, PRO1184 is a promising development candidate for the treatment of FRα-expressing solid tumors. A first in human phase 1/2 study in patients with advanced solid tumors is currently recruiting (NCT 05579366).
• Discussing the exciting potential of PRO1184, as it is expected to be active in ovarian, endometrial, nonsmall cell lung, and breast cancer, and mesothelioma • Outlining novel hydrophilic linker confers optimal PK/PD properties and potential for wide therapeutic window • Describing efficient clinical trial design based on PRO1184 attributes
The pharmacokinetics (PK) of PRO1184 were similar to that of the unconjugated parent antibody in rats. PRO1184 has the potential for a meaningful therapeutic window to provide an appropriate benefit to risk profile for patients with FOLR1-expressing cancers.